Metastatic Solid Tumors Clinical Trials

89 recruitingLast updated: June 17, 2026

There are 89 actively recruiting metastatic solid tumors clinical trials across 33 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Metastatic Solid Tumors Trials at a Glance

89 actively recruiting trials for metastatic solid tumors are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 1 with 80 trials, with the heaviest enrollment activity in Houston, Nashville, and New York. Lead sponsors running metastatic solid tumors studies include Daiichi Sankyo, Innovent Biologics (Suzhou) Co. Ltd., and Hanmi Pharmaceutical Company Limited.

Browse metastatic solid tumors trials by phase

Treatments under study

About Metastatic Solid Tumors Clinical Trials

Looking for clinical trials for Metastatic Solid Tumors? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 89 trials

Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 1

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumors
Erasca, Inc.200 enrolled5 locationsNCT06983743
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 1

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.50 enrolled1 locationNCT07607054
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 2

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.150 enrolled1 locationNCT07646626
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled9 locationsNCT07238075
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612189
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.189 enrolled14 locationsNCT06248411
Recruiting
Phase 1Phase 2

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.120 enrolled2 locationsNCT06922357
Recruiting
Phase 1Phase 2

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.111 enrolled1 locationNCT07469774
Recruiting
Phase 1

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech41 enrolled5 locationsNCT07541534
Recruiting
Phase 1

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
Changchun GeneScience Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07407504
Recruiting
Phase 1

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612176